Surgery Partners, Inc.(SGRY)Earnings, Financials & Key RatiosSurgery Partners, Inc. (SGRY) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to achieve profitability, evidenced by a -4.4% net margin in 2026Q1, combined with a high debt-to-EBITDA ratio of 38.62, suggests significant long-term solvency risks.
Surgery Partners, Inc. (SGRY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Surgery Partners, Inc. (SGRY) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.03vs $0.15+80.0% | $811Mvs $798M+1.7% |
| Q2 2026 | Mar 2, 2026 | $0.12vs $0.31-61.3% | $885Mvs $867M+2.1% |
| Q4 2025 | Nov 10, 2025 | $0.13vs $0.19-31.6% | $822Mvs $867M-5.2% |
| Q3 2025 | Aug 5, 2025 | $0.17vs $0.16+6.3% | $826Mvs $824M+0.3% |
Recent stock market news and headlines for Surgery Partners, Inc. (SGRY)
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Surgery Partners (SGRY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
The average of price targets set by Wall Street analysts indicates a potential upside of 26.1% in Surgery Partners (SGRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Key metrics vs top competitors for Surgery Partners, Inc. (SGRY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.17 | $2.25B | -28.15 | 6.24% | -2.35% | -2.18% | — | |
| $71.80 | $1.09B | 50.56 | 16.33% | 1.52% | 1.36% | — | |
| $16.51 | $2.05B | 13.99 | 5.12% | 2.42% | 6.57% | — | |
| $35.45 | $663.05M | 14.35 | 2.63% | 14.27% | 17.85% | — | |
| $216.40 | $3.38B | 28.21 | 16.38% | 8.11% | 11.63% | — | |
| $105.97 | $1.98B | 20.34 | 23.21% | 6.89% | 9.34% | — |
Surgery Partners, Inc. (SGRY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Surgery Partners, Inc. (SGRY) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Mar 2, 2026·SEC
Dec 16, 2025·SEC
Get notified when SGRY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Surgery Partners, Inc. (SGRY) stock FAQ — growth, dividends, profitability & financials explained
Surgery Partners, Inc. (SGRY) reported $3.34B in revenue for fiscal year 2025. This represents a 1075% increase from $284.6M in 2013.
Surgery Partners, Inc. (SGRY) grew revenue by 6.2% over the past year. This is steady growth.
Surgery Partners, Inc. (SGRY) reported a net loss of $76.1M for fiscal year 2025.
Surgery Partners, Inc. (SGRY) has a return on equity (ROE) of -2.2%. Negative ROE indicates the company is unprofitable.
Surgery Partners, Inc. (SGRY) generated $208.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
